Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23317199 | 0.88 | TSHR (0.37) | LMNAALDH1A1HPGDNLRP3TSHR | |
| SCHEMBL23317545 | 0.88 | PKM (0.34) | LMNAALDH1A1HPGDNLRP3TSHR | |
| SCHEMBL23317396 | 0.88 | LMNA (0.43) | LMNAALDH1A1HPGDNLRP3TSHR | |
| SCHEMBL23317298 | 0.86 | LMNA (0.46) | LMNAALDH1A1HPGDNLRP3TSHR | |
| SCHEMBL23317381 | 0.85 | HPGD (0.44) | LMNAALDH1A1HPGDNLRP3TSHR | |
| SCHEMBL23317409 | 0.85 | KMT2A (0.38) | ALDH1A1HPGDNLRP3TSHRPOLB | |
| SCHEMBL23317688 | 0.85 | LMNA (0.42) | LMNAALDH1A1HPGDTSHRNPSR1 | |
| SCHEMBL23294937 | 0.84 | ATM (0.46) | LMNAALDH1A1NLRP3L3MBTL1POLB | |
| SCHEMBL23317552 | 0.84 | GPR35 (0.36) | LMNAALDH1A1HPGDNLRP3NPSR1 | |
| SCHEMBL23317692 | 0.83 | TSHR (0.46) | LMNAALDH1A1HPGDNLRP3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | LMNA 3757/4885ALDH1A1 3411/4885HPGD 1633/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | LMNA 3757/4885ALDH1A1 3411/4885HPGD 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.